Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Medical - Devices

Healthcare
$17.05 +1.53%

+$0.24 today

Market cap
$1.19B
Beta
1.57
P/E (TTM)
-11.3
EPS (TTM)
-$1.38
52W Low $9.98High $29.65

Volume 2.35M

Average 2.43M

TNDM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Tandem Diabetes Care, Inc.NASDAQ: TNDM

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $15.66M fell 38.6% year over year, behind the -21.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 22.1% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Stock-based compensation amounted to 9.1% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -38.6% toward the trailing-twelve-month pace of -21.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.66M-22.1% QoQ
Last fiscal yearDec 2025
$92.38M-8.9% YoY
LTMMar 2026
$82.55M-21.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.6%——
1 year-8.9%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
92.38M USD
Year-over-year change
-8.9%
4-year CAGR
+11.0%

Stock-Based Compensation vs competitors

How TNDM compares with its peers on the latest reported figures

  • TNDM's LTM Mar 2026 stock-based compensation of $82.55M is the 2nd largest of the 8 companies compared; the peer median is $18.99M.
  • Its year-over-year change of -21.3% is the 5th highest of 7, against a peer median of +6.0%.
  • Stock-based compensation amounts to 8.0% of revenue for TNDM, versus a peer median of 3.6%.
TNDM Competitors Peer median
Stock-Based Compensation for TNDM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DXCMDexCom, Inc.LTM Jun 2026$162.4M -2.3%+8.1%3.3%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$82.55M -21.3%+2.8%8.0%
PODDInsulet CorporationLTM Jun 2026$77.9M +22.1%+15.3%2.6%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$47M —+9.5%1.5%
BBNXBeta Bionics, Inc.LTM Mar 2026$18.99M +142.5%+39.0%17.2%
MNKDMannKind CorporationLTM Mar 2026$14.49M -36.6%—4.0%
SENSSenseonics Holdings, Inc.LTM Mar 2026$10.59M +14.3%+5.6%26.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$7.81M -26.4%+28.7%—
MMEDVMiniMed Group, Inc.—— ———
Peer median (excluding TNDM) $18.99M+6.0%+12.4%3.6%

Competitors are the stored peer set for TNDM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.57M(94.59M)(222.61M)(96.03M)(204.71M)
Depreciation & Amortization13.85M14.33M15.72M16.61M13.84M
Deferred Income Tax00000
Stock-Based Compensation60.75M84.92M88.08M101.38M92.38M
Change in Working Capital14.37M(4.65M)(17.69M)(11.78M)(23.04M)
Accounts Receivables(30.98M)(7.83M)4.28M(20.8M)(56.81M)
Inventory(4.95M)(42.45M)(46.05M)5.81M24.82M
Accounts Payables10.28M24.49M(4.86M)(2.39M)2.23M
Other Working Capital40.03M21.14M28.96M5.6M6.73M
Other Non-Cash Items6.82M50.46M104.7M14.04M111.81M
Operating Cash Flow111.36M50.46M(31.81M)24.23M(9.72M)
Capital Expenditures(23.51M)(34.1M)(26.8M)(19.23M)(19.95M)
Acquisitions (Net)0(25.72M)(69.5M)00
Purchases of Investments(733.39M)(467.65M)(535.66M)(264.31M)(85.66M)
Sales of Investments570.02M569.49M546.22M306.46M257.07M
Other Investing Activities(9.33M)(8.86M)0(46.4M)(78.59M)
Investing Cash Flow(186.88M)33.17M(85.74M)(23.48M)72.88M
Debt Repayment00044.91M(40.76M)
Common Stock Issued017.55M0(6.73M)(2.61M)
Common Stock Repurchased000(30M)0
Dividends Paid00000
Other Financing Activities51.93M(675K)4.11M183K0
Financing Cash Flow51.93M16.88M4.11M8.37M(43.37M)
Effect of Forex Changes153K827K(212K)1.26M1.61M
Net Change in Cash(23.43M)101.34M(113.65M)10.37M21.4M
Free Cash Flow87.85M16.37M(58.61M)4.99M(29.67M)

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Intrinsic Alpha fair value

Locked

Current Price

$17.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.